SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device industry, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its ReeAmber peripheral balloon dilation catheter. This next-generation device is designed to address a broad spectrum of vascular interventions.
The ReeAmber catheter is indicated for the treatment of stenosis lesions in various arteries, including the iliac, femoral, popliteal, inferior popliteal, and renal arteries. Additionally, it is approved for obstructive lesions in both autogenous and synthetic arteriovenous dialysis fistulas. The product’s versatility extends to posterior dilation of balloon and self-expanding stents in peripheral blood vessels, making it a valuable tool in vascular medicine.
The approval of the ReeAmber catheter by the NMPA underscores Shanghai MicroPort’s commitment to innovation and the development of advanced medical devices that meet the needs of patients and healthcare providers. The device’s ability to cater to a wide range of vascular applications is expected to enhance clinical outcomes and provide more treatment options in the field of peripheral artery disease.- Flcube.com
